MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
18.24
+0.83
+4.77%
After Hours: 18.66 +0.42 +2.30% 19:45 05/12 EDT
OPEN
18.43
PREV CLOSE
17.41
HIGH
19.15
LOW
17.84
VOLUME
2.23M
TURNOVER
--
52 WEEK HIGH
35.25
52 WEEK LOW
13.53
MARKET CAP
1.83B
P/E (TTM)
-3.9547
1D
5D
1M
3M
1Y
5Y
1D
Beam : FDA Grants RMAT Designation To BEAM-302 For Alpha-1 Antitrypsin Deficiency Treatment
NASDAQ · 4h ago
Beam Therapeutics announces FDA grants RMAT designation to BEAM-302
TipRanks · 11h ago
Beam Therapeutics granted FDA’s Regenerative Medicine Advanced Therapy designation
Seeking Alpha · 11h ago
BEAM THERAPEUTICS ANNOUNCES U.S. FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO BEAM-302 FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Reuters · 11h ago
BEAM THERAPEUTICS- PLANS TO DOSE FIRST PATIENT IN PART B, WHICH WILL INCLUDE AATD PATIENTS WITH MILD TO MODERATE LIVER DISEASE, IN H2 2025
Reuters · 11h ago
Weekly Report: what happened at BEAM last week (0505-0509)?
Weekly Report · 22h ago
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
NASDAQ · 3d ago
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
NASDAQ · 3d ago
More
About BEAM
More
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Recently
Symbol
Price
%Change

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.